Advances and effectiveness of the immunotherapy after liver transplantation

Transplant recipients usually have increased chances of graft rejection and graft vs host disease, requiring chronic immunosuppressive therapy. Nonetheless, long-term immunosuppression risks malignancies such as skin cancer, lymphoma, and Kaposi sarcoma. However, there are very few studies that incl...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastrointestinal surgery 2022-06, Vol.14 (6), p.629-631
Main Authors: Vulasala, Sai Swarupa R, Onteddu, Nirmal K, Kumar, Sindhu P, Lall, Chandana, Bhosale, Priya, Virarkar, Mayur K
Format: Article
Language:English
Subjects:
Letter to the Editor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transplant recipients usually have increased chances of graft rejection and graft vs host disease, requiring chronic immunosuppressive therapy. Nonetheless, long-term immunosuppression risks malignancies such as skin cancer, lymphoma, and Kaposi sarcoma. However, there are very few studies that included solid organ transplant recipients while studying the efficacy of immunotherapy. “Immunotherapy after liver transplantation: Where are we now?” is a study, where the authors described the mechanism of action and outcomes of immune checkpoint inhibitors specific to liver transplant recipients. The authors reported the graft rejection rates and the factors contributing to the rejection in the liver transplant recipients.
ISSN:1948-9366
1948-9366
DOI:10.4240/wjgs.v14.i6.629